GENERAL GUIDANCE (SA MANUFACTURER RECOMMENDATIONS)

INITIATION

For patients with type 2 diabetes mellitus, the recommended total daily starting dose of insulin degludec/insulin aspart is 10 units once daily with a meal followed by individual dosage adjustments.

For patients with **type 1 diabetes mellitus,** insulin degludec/insulin aspart is to be used once daily at mealtime and a short-/rapid-acting insulin should be used at the remaining meals with individual dosage adjustments.

The recommended starting dose of insulin degludec/insulin aspart is 60-70% of the total daily insulin requirements.

TRANSFER FROM OTHER INSULIN MEDICINAL PRODUCTS

Close glucose monitoring is recommended during transfer and in the following weeks.

PATIENTS WITH TYPE 1 DIABETES

For patients with type 1 diabetes mellitus, the recommended starting dose of insulin degludec/insulin aspart is 60-70 % of the total daily insulin requirements in combination with short-/rapid-acting insulin at the remaining meals followed by individual dosage adjustments.

Doses and timing of concurrent short-/rapid-acting insulin products may need to be adjusted.

PAEDIATRIC POPULATION

Insulin degludec/insulin aspart can be used in adolescents and children from the age of 2 years.

When **changing from another insulin** regimen to insulin degludec/insulin aspart, **dose reduction of total insulin** needs to be considered on **an individual basis** in order to minimise the risk of hypoglycaemia.

Insulin degludec/insulin aspart should be used with **special caution** in children 2 to 5 years old because data from the clinical trial indicate that there may be a higher risk for severe hypoglycaemia in children in this age group.